Clinical outcomes of atezolizumab versus standard-of-care docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.

"Conflict of interest RM: Advisory Board: AstraZeneca, Takeda, Guardant health, Janssen, Novocure, Turning Point, OncoHost. RC: Stocks: Eli Lilly and company, Gilead Sciences. YZ: Research Funding Support: PDS Biotechnology, Zai Lab, Incyte, Mirati, alpine, Pfizer, Merck, Elucida Oncology. YL: Advisory board: AstraZeneca Pharmaceuticals, Janssen Pharmaceutical, Lilly Oncology, Turning Point Therapeutics, Cardinal Health, Clinical Education Alliance, Oncohost, Mirati Therapeutics Honorarium to Mayo Clinic; Research Funding Support: Merck, Tolero Pharmaceuticals, AstraZeneca, Blueprint Medicines, Sun Pharma, Mirati Therapeutics, Genmab, EMD Serono, Jacobio pharma, TOPALLIAN, Daiichi Sankyo. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article."